Log In
Print
BCIQ
Print
Print this Print this
 

Dymista, azelastine/fluticasone (MP29-02)

  Manage Alerts
Collapse Summary General Information
Company Meda AB
DescriptionCombination of azelastine and fluticasone propionate in a single nasal spray delivery device
Molecular Target
Mechanism of Action 
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentMarketed
Standard IndicationRhinitis
Indication DetailsTreat allergic rhinitis and rhinoconjunctivitis; Treat chronic allergic or non-allergic rhinitis; Treat seasonal allergic rhinitis (SAR)
Regulatory Designation

Partner

Cipla Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today